Completed PHASE3 INTERVENTIONAL NCT00092027

A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women

Sponsor: Organon and Co

Conditions Postmenopausal Osteoporosis

Interventions Comparator: placebo / Duration of Treatment: 6 months MK0217, alendronate sodium/Duration of Treatment: 6 months

Updated 8 times since 2017 Last updated: Aug 12, 2024 Started: Mar 19, 2003 Primary completion: Mar 15, 2004 Completion: Mar 15, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00092027, this PHASE3 trial focuses on Postmenopausal Osteoporosis and remains completed. Sponsored by Organon and Co, it has been updated 8 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Apr 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Apr 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.